alpha fetoprotein

Overview

Alpha-fetoprotein (AFP) is a glycoprotein and well-established serum tumor marker, best known for its clinical association with hepatocellular carcinoma (HCC). It is also used in the evaluation of other AFP-producing malignancies, including alpha-fetoprotein-producing gastric cancer, where elevated serum AFP can correlate with tumor stage and prognosis. In routine practice, AFP is primarily valued as a biomarker for detection, risk stratification, and disease monitoring rather than as a standalone diagnostic test.

Beyond its biomarker role, recent research has increasingly examined AFP as a biologically active molecule in cancer. In hepatocellular carcinoma, AFP has been investigated as a regulator of cancer stemness and tumor progression, including signaling through the PI3K/Akt signaling pathway. This broader functional perspective has prompted studies of AFP in relation to tumor biology, glycoprotein recognition, and assay development, alongside related cancer markers such as carcinoembryonic antigen, epithelial cell adhesion molecule, CD44, Erb-b2 receptor tyrosine kinase 2, and tumor protein p53.

Focus of Latest Publications

Recent publications have established alpha-fetoprotein as a critical biomarker in multiple malignancies, particularly in hepatocellular carcinoma and gastric cancer. In HCC, log-transformed AFP levels combined with des-γ-carboxy prothrombin have emerged as predictors of early recurrence following hepatectomy, with nomogram-based risk stratification enabling better patient prognostication. In gastric cancer, AFP-producing gastric cancer represents a distinct clinical entity characterized by aggressive biological behavior and elevated serum AFP levels that correlate closely with tumor stage and patient prognosis. The prognostic value of AFP is further enhanced when measured alongside other markers such as carcinoembryonic antigen, human chorionic gonadotropin, and PIVKA-II, with concurrent elevation indicating high malignant potential and poor outcomes.

Beyond its role as a prognostic indicator, intratumoral AFP has been shown to actively participate in tumor pathophysiology. In gastric cancer, AFP expression promotes tumor invasiveness and metastasis by modulating immune cell activity, contributing to an immunosuppressive tumor microenvironment that enhances the malignant potential of AFP-producing tumors. This immunosuppressive capacity may explain the differential response to immune checkpoint inhibitors, which have demonstrated preliminary efficacy in some AFP-producing gastric cancer cases.

Recent technological advances have dramatically improved AFP detection capabilities for both research and clinical diagnostics. Multiple biosensing platforms have achieved ultrasensitive detection, including polymeric membrane ion-selective electrodes achieving limits as low as 1.92 pg/mL, microfluidic photonic crystal arrays detecting AFP at 0.1 ng/mL with direct correlation to clinical ELISA standards, and nanozyme-enhanced lateral flow immunoassays achieving 1300-fold improvements over conventional gold nanoparticles. Exosome-based detection strategies employing dual-mode readouts with AFP-mediated signal tagging have achieved sensitive quantification of circulating HepG2-derived exosomes, with clinical validation distinguishing liver cancer patients from healthy controls with statistical significance.

Point-of-care diagnostic technologies coupling AFP detection with simplified sample preparation workflows have advanced toward practical clinical implementation. Copper-based metal-organic framework immunosensors enhanced with neocuproine achieve rapid AFP quantification (5 min assay time, 1.4 ng/mL limit of detection) with validated performance in serum samples. Microfluidic integration of photonic crystals with on-chip membrane filtration replaces conventional centrifugation while maintaining high accuracy, supporting deployment of laboratory-grade hepatic disease diagnostics in resource-limited settings.

Key Publications

• NEWJan Log-transformed α-Fetoprotein and Des-γ-carboxy Prothrombin Predict Early Recurrence After Hepatectomy for Hepatocellular Carcinoma. (In vivo (Athens, Greece), 2026, PMID 42379778): "We evaluated the impact of log-transformed serum alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) levels on early hepatocellular carcinoma (HCC) recurrence after hepatectomy and developed a nomogram for risk stratification."
• May DNA Tetrahedron-Mediated Sensing Platform on a Single Gold Nanowire: Special Signal Amplification, Self-Referencing Capability, and Cross-Validated Exosome Detection for Liver Cancer Liquid Biopsy. (ACS sensors, 2026, PMID 42190059): "The platform features three exosome-specific design strategies: CD63 aptamer-functionalized DNA tetrahedrons (AD-NTH) with well-controlled probe orientation, spacing, and accessibility to enhance exosome capture efficiency and mitigate interfacial steric hindrance; dual recognition via CD63-mediated capture and AFP-mediated signal tagging for improved specificity toward HepG2-derived exosomes; and a ratiometric SERS/electrochemical dual-mode readout on a unified substrate to enhance signal reliability."
• May Glycoprotein biosensor boosted by signal amplification of heparin polysaccharide and insights into glycan-lectin recognition. (Mikrochimica acta, 2026, PMID 42174235): "Alpha-fetoprotein (AFP) is one representative glycoprotein tumor marker, which has served as a useful predictive and prognostic biomarker in clinical practice for hepatocellular carcinoma."
• Jun Biomedical publication details. (PubMed Database, 2026, PMID 42132692)
• May Hierarchical Mesochannel-Confined Nanozyme Reactors Propelling Gold Amplification Immunoassays for Ultrasensitive Point-of-Care Diagnostics. (Analytical chemistry, 2026, PMID 42063290): "The limit of detection for FeMPPt-labeled vLFIA for qualitative/quantitative detection of cardiac troponin I and alpha-fetoprotein was 125/230-fold and 1300/1300-fold lower than that for AuNP-labeled vLFIA, respectively."
• Apr [Novel clinical insights and frontier issues in alpha- fetoprotein-producing gastric cancer]. (Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2026, PMID 41978393): "As a serum tumor marker, alpha-fetoprotein (AFP) is typically highly elevated in AFPGC and correlates closely with tumor T-stage and patient prognosis."
• Jun Neocuproine boosting catalytic activity of copper-based metal-organic frameworks for sensitive colorimetric immunosensor. (Biosensors & bioelectronics, 2026, PMID 41764904): "As a proof-of-concept, alpha-fetoprotein (AFP) was used to validate the feasibility and practicality of the proposed immunosensor."